The Liquid Biopsy Research Group

Research group focused on circulating biomarkers and clinical utility-oriented translational research

[Lorenzo Foffano @lfoffano97]

Can #fragmentomics become a new monitoring #biomarker in metastatic breast cancer? 🔬

👉 Here we explore a mutation-agnostic, cost-effective approach tested in the MAGNETIC.1 trial—a longitudinal study of first-line HR+/HER2- MBC.

https://t.co/c7w9ir8iZ5

[Lorenzo Gerratana @LGerratana]

🏁 Our program on cellular residual disease in triple negative breast cancer is about to launch!

Detecting circulating tumor cells in early #TNBC will provide deeper insights into the metastatic process and #immunotherapy response

#BreastCancer #LiquidBiopsy #CTC @CroAviano

[The Liquid Biopsy Research Group @LiquidBioGroup]

🔬 Exciting Liquid Biopsy session under the patronage of the International Society of Liquid Biopsy

📍 View the full program and register here: https://t.co/Iv2GtNH6xn

#FocusOnTop #LiquidBiopsy #CTCs #ctDNA #PrecisionOncology #FTOP25 #BreastCancer @isliquidbiopsy

[The Liquid Biopsy Research Group @LiquidBioGroup]

🗓️Mark Your Calendars!

Join us at FOCUS on TOP in Udine, Italy, on March 17-18, 2025!

📍 Venue: Hotel Là di Moret, Udine, Italy
🚆 Train: Udine railway station
✈️ Airports: Venice Marco Polo, Trieste - Friuli Venezia Giulia
🌐 More Info: https://t.co/Iv2GtNH6xn

[The Liquid Biopsy Research Group @LiquidBioGroup]

🎤 Hear it from our speakers!

On March 17, 2025, at 14:00, @ReduzziCarol will take the stage at FOCUS on TOP in the #LiquidBiopsy Session, exploring the role of circulating tumor cells (#CTCs) in #MRD monitoring with #ctDNA.

Program and registration: 👇
https://t.co/6opTBEPkOX

[Lorenzo Gerratana @LGerratana]

CDK4/6 inhibitors: mechanisms of resistance and where to find them.
An outside of the box review

Main takeaways:
🛑RB1 loss in #ctDNA predicts poorer PFS
⚠️CCNE1 gain impacts PALOMA-3 outcomes
🧩Role of ESR1 still unclear

Read more👇
https://t.co/tqZgoY5qUb

#bcsm #BreastCancer

[The Liquid Biopsy Research Group @LiquidBioGroup]

With the growing efficacy of new antiHER2 agents, biomarker-driven de-escalation will become increasingly crucial for #PrecisionMedicine in #BreastCancer

#bcsm

@lindacucciniel1 @BlondeauxEva

[Lorenzo Gerratana @LGerratana]

Ancillary analysis of the GIM14 study
shows features linked to radiologic complete response (rCR) in HER2+ #MBC:

🌡️ HER2 IHC 3+
🩻 Non-visceral involvement
🎯 1 metastatic site

Setting the stage for the GIM36/INSPIRE1 #liquidbiopsy #MRD trial #bcsm

https://t.co/8Il0eNicoi

[The Liquid Biopsy Research Group @LiquidBioGroup]

Intriguing data presented by @lfoffano97 at the #SABCS24 poster session on how #ctDNA can be leveraged to enhance disease monitoring in metastatic #BreastCancer.

Paving the way to a new #liquidbiopsy informed RECIST

@CtcLaboratory #PrecisionMedicine #bcsm

[The Liquid Biopsy Research Group @LiquidBioGroup]

Our @LGerratana shows the perspectives of adjuvant treatment de-escalation at the #AIOM24 #breastcancer educational session. #liquidbiopsy will play a crucial role in transitioning from prognostication to actual monitoring. #ctDNA #PrecisionMedicine @uniud @CroAviano

[MediMix @Medi_Mix]

🔬 #ASCO2024 Insight: Dr @LGerratana discusses the genomic profiling of PR-negative and ER-low breast cancer subtypes. ER-low tumours show a mutational profile similar to triple-negative breast cancer, suggesting benefits from immunotherapy.

[Lorenzo Foffano @lfoffano97]

#ctDNA is gaining importance in #breastcancer. But what are its real clinical prospects? Excited to share our perspective: 'Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?' 👉 https://t.co/nHe86yW06G

[Lorenzo Gerratana @LGerratana]

Is ER low metastatic #BreastCancer a TNBC-like disease subtype?

Check our circulating tumor DNA analysis

📍Poster Bd # 17 - Hall A, Metastatic Breast Cancer session
⏱️ 9:00 AM - 12:00 PM #ASCO24 #ctDNA #bcsm #liquidbiopsy

[Lorenzo Gerratana @LGerratana]

Say hello to OLGA, @CroAviano persOnaLized oncoloGy cAre flow platform

It’s time to move from the paradigm of #PrecisionMedicine in #Oncology to a broader concept of #Personalized #Care, where treatments and monitoring strategies are holistically tailored around every person.

[Lorenzo Gerratana @LGerratana]

Great opportunity to get in touch with the International Society of Liquid Biopsy (ISLB @isliquidbiopsy) at booth 10027! #ASCO24 #LiquidBiopsy

[International Society of Liquid Biopsy @isliquidbiopsy]

Join Francois-Clement Bidard at the 20th Anniversary of Circulating Tumor Cells in Granada, Spain from May 24-25, 2024.

Francois-Clement Bidard, MD PhD, is a Professor of Medical Oncology at Institut Curie & Versailles University, and also the vice-chair or the French breast cancer research group UCBG/Unicancer.

For more information, please contact [email protected].

#CTC20thAnniversary #SpeakerSpotlight
@MJOSESERRANO19
@MCristofanill

[International Society of Liquid Biopsy @isliquidbiopsy]

Be part of the 20th Anniversary of Circulating Tumor Cells, organized by ISLB!

📅 Save the date for May 24 - 25, 2024, and join us as we unveil the impact of Circulating Tumor Cells, exploring two decades of discovery and clinical advancements in solid tumors.

Chairs:
@MCristofanill
@MJOSESERRANO19

Hosted at Centro Pfizer-University of Granada-Junta De Andalucia De Genomica E Investigación Oncologica, Granada, Spain.

Don't miss this opportunity to be part of the future of cancer research and treatment! More information please write to [email protected]

[Lorenzo Gerratana @LGerratana]

What is the role of synonymous mutations (SYN) and variants of unknown significance (VUS) detected though #ctDNA next generation sequencing?

Some interesting insights presented by @Elisabetta_mol at the #SABCS23 poster session

#LiquidBiopsy #MBC

[Lorenzo Gerratana @LGerratana]

Check our companion posters on genetic and epigenetic #ctDNA profiling according to PR status in metastatic #breastcancer.

🔴during 1st line ET
🔼 ESR1 promoter methylation in PRpos

🔴after 1st line:
🔼ESR1 mut in PRpos #MBC
🔼GATA3 mut in PRneg #MBC

#SABCS23 #liquidbiopsy

[Lorenzo Gerratana @LGerratana]

Moving from prognostication to pattern of progression at the #ESMO23 poster session with @lindacucciniel1 . Hazard distribution has different patterns across clinical and #LiquidBiopsy subgroups: can we #personalize disease monitoring in metastatic #BreastCancer?

[Lorenzo Gerratana @LGerratana]

A recent prospective study delved into baseline pharmacological profiling in patients treated for metastatic #BreastCancer using #palbociclib

🧵3/5

https://t.co/quyIncmpAt

#MBC